ArticleFrontiers in health services2026
Differentiated regulation and health spending growth: European evidence from the new SCORE index.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rising healthcare expenditure poses a major fiscal challenge for European governments, driven in part by preventable diseases associated with tobacco use, alcohol consumption, and sugar-sweetened beverages (SSBs). Although regulatory interventions are widely used to address these risk factors, most evaluations focus on overall policy stringency and implicitly assume homogeneity within product categories. This overlooks the potential importance of risk-proportional regulatory designs that differentiate products according to their relative health risks. Methods: This study investigates whether differences in the design of regulatory frameworks for tobacco, alcohol, and SSBs are associated with variations in healthcare spending growth across European countries. Specifically, it compares conventional measures of regulatory restrictiveness with a risk-proportional approach that calibrates regulatory burdens according to the relative risks of products within each category. The relationship between regulatory design, healthcare expenditure growth, and population health outcomes is examined using cross-country statistical analysis. Results: The analysis indicates that risk-proportional regulatory frameworks are more strongly associated with lower healthcare spending growth and improved population health outcomes than uniform measures of policy stringency. Regulatory systems that incentivize substitution toward lower-risk alternatives are associated with a more favourable overall risk profile of consumption. Discussion: These findings suggest that the design of health regulations, rather than their overall restrictiveness alone, may play an important role in promoting fiscal sustainability. By encouraging harm reduction within product categories, risk-proportional regulation may contribute to reducing the long-term burden of preventable diseases and the associated pressure on national healthcare budgets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.